Petros Grivas, MD, PhD

No bio available.

Financial relationships

  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Immunity Bio
    Date added:
    06/15/2024
    Date updated:
    02/28/2025
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Asieris Pharmaceuticals
    Date added:
    06/15/2024
    Date updated:
    02/28/2025
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Abbvie
    Date added:
    06/15/2024
    Date updated:
    02/28/2025
  • Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Pfizer
    Date added:
    06/15/2024
    Date updated:
    02/28/2025
  • Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    BMS
    Date added:
    06/15/2024
    Date updated:
    02/28/2025
  • Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Merck
    Date added:
    06/15/2024
    Date updated:
    02/28/2025
  • Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    QED Therapeutics
    Date added:
    06/15/2024
    Date updated:
    02/28/2025
  • Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Gilead Sciences
    Date added:
    06/15/2024
    Date updated:
    02/28/2025
  • Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Acrivon Therapeutics
    Date added:
    06/15/2024
    Date updated:
    02/28/2025
  • Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    ALX Oncology
    Date added:
    06/15/2024
    Date updated:
    02/28/2025

Pages

Return to Recorded Webcast - Optimizing Immuno-Oncology: Innovations in Immune Checkpoint Inhibitor Delivery